Biora Therapeutics, Inc. has entered a research collaboration with a large pharmaceutical company for its BioJet Systemic Oral Delivery Platform. The agreement provides funding to test the platform’s ability to achieve bioavailability through oral delivery of the undisclosed collaborator’s molecules to the small intestine in animal models.

The BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases.

“This most recent deal shows that we are making great progress, and that progress is being recognized by others,” said Adi Mohanty, CEO of Biora Therapeutics. “We’re currently progressing two of our research collaboration studies to completion, are actively conducting studies with a third, and are looking forward to performing studies with this most recent big pharma collaborator during the first quarter,”

Mohanty added: “Oral delivery of large molecules continues to be the holy grail of drug delivery. Our BioJet technology, with its strong patent protection, features several advantages that include delivery of multi-milligram liquid doses with minimal formulation changes to the planned drug, and we continue to demonstrate category-leading oral bioavailability.”